Compare FTK & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | IMTX |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.2M | 992.8M |
| IPO Year | 1997 | 2020 |
| Metric | FTK | IMTX |
|---|---|---|
| Price | $24.57 | $6.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $39.42 | $15.97 |
| AVG Volume (30 Days) | 270.8K | ★ 1.0M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $62.65 | N/A |
| Revenue Next Year | $11.85 | $14.22 |
| P/E Ratio | $34.50 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $13.19 | $6.06 |
| 52 Week High | $39.67 | $12.41 |
| Indicator | FTK | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 36.00 |
| Support Level | $21.45 | N/A |
| Resistance Level | $25.39 | $7.95 |
| Average True Range (ATR) | 1.89 | 0.47 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 35.44 | 19.81 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.